Vinjamoori says he discussed with White House regulators what regulated peptide access should look like, arguing many Americans already use them.
Recap by typeshit. Post by Anant Vinjamoori, MD on X.
The think tank argues regulated compounding beats 'research use only' sellers, noting an FDA panel voted to add six peptides despite staff advising against all seven.
In a JAMA Viewpoint, CSPI authors argue a peptide-friendly advisory panel stacked with industry-tied members threatens drug approval integrity.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Washington Times asks physicians about the growing talk of GLP-1 drugs as an anti-aging fix, and they urge caution before reading too much into it.
Researchers used AI to design a short peptide aimed at cells that have stopped dividing, which build up with age and in response to DNA damage.
Loading…